7:11AM Alkermes beats by $0.07, beats on revs; raises FY13 EPS, rev guidance above consensus (ALKS) 18.52 : Reports Q2 (Sep) earnings of $0.17 per share, $0.07 better than the Capital IQ Consensus Estimate of $0.10; revenues rose 72.2% year/year to $124 mln vs the $122.49 mln consensus.
Co raises guidance for FY13, sees EPS of $0.88-1.02 vs. $0.77 Capital IQ Consensus Estimate; sees FY13 revs of $510-540 mln vs. $519.09 mln Capital IQ Consensus Estimate.
"In September, we updated our expectations for improved non-GAAP net income and free cash flow for fiscal 2013, reflecting the impact of the successful refinancing of the term loans used to fund the merger. Today, we are further improving our financial expectations for fiscal 2013 based on strong operational performance in the first six months, and we now expect Alkermes to generate between $120 million and $140 million in non-GAAP net income this fiscal year."
Co raises guidance for FY13, sees EPS of $0.88-1.02 vs. $0.77 Capital IQ Consensus Estimate; sees FY13 revs of $510-540 mln vs. $519.09 mln Capital IQ Consensus Estimate.
"In September, we updated our expectations for improved non-GAAP net income and free cash flow for fiscal 2013, reflecting the impact of the successful refinancing of the term loans used to fund the merger. Today, we are further improving our financial expectations for fiscal 2013 based on strong operational performance in the first six months, and we now expect Alkermes to generate between $120 million and $140 million in non-GAAP net income this fiscal year."
Recent ALKS News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2026 12:08:26 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2026 12:04:37 AM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 05/22/2026 11:59:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:59:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 08:57:44 PM
- Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences • Business Wire • 05/21/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:10:47 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/13/2026 09:03:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/12/2026 11:07:58 AM
- Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia • Business Wire • 05/12/2026 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/05/2026 08:30:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 11:05:17 AM
- Alkermes plc Reports First Quarter 2026 Financial Results • Business Wire • 05/05/2026 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/04/2026 08:30:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/02/2026 01:05:20 AM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/01/2026 08:51:50 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/01/2026 08:22:08 PM
- Alkermes to Report First Quarter Financial Results on May 5, 2026 • Business Wire • 04/21/2026 08:05:00 PM
- Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting • Business Wire • 04/16/2026 11:00:00 AM
- Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry • Business Wire • 04/14/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/06/2026 11:56:39 PM

